Hypoglycemia Drug Market Size, Company Share, Trends Analysis and Forecast 2021-2030
All the vital news, analysis, and commentary curated by our industry experts.
The hypoglycemia drug sales have been valued to $423.5 million across the 7MM in 2020 growing at a CAGR of more than 4%. The US has contributed more than 90% of the sales that is primarily due to the significantly higher prices of glucagons in the US, a relatively high diagnosed prevalence of type 1 diabetes (T1D) and high incidence rate of post-bariatric hypoglycemia (PBH). The next largest individual markets are Italy and Germany. Therefore, altogether the 5EU countries make up to more than 5% of the total market. Japan is found to be the lowest, with its low historic prescription rate of glucagon.
The hypoglycemia growth has been augmented by the increase in T1D prevalence, as well as the increased uptake of second-generation glucagons and the launch of dual-hormone pump systems that are compatible with liquid-stable glucagons. The launches of these products will offset the drop in sales caused by the relative decrease in incidence of severe hypoglycemia as the adoption of glucose monitors increases.
In addition, the forecast period will see the launch of the first treatment to directly address PBH. As this is a targeted treatment, it will be able to generate a significant market share and will ultimately drive the growth of the market. The report will cover the seven major pharmaceutical markets (7MM)- The US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan during the forecast period.
Overview of the hypoglycemia drugs market
For more insights on this report, download a free report sample
What are the market dynamics and market barriers for the hypoglycemia drug market?
The major drivers of the growth within the hypoglycemia drugs market includes the: significant increase in T1D diagnosed prevalence, uptake of second-generation glucagons both as nasal and liquid-stable formulation and the launch of the first treatment for post-bariatric hypoglycemia.
The major barriers to the growth of the hypoglycemia market will include: the increasing prioritization of hypoglycemia prevention, and the development of targeted treatments that address the etiology of hypoglycemia, the increase in glucose monitors, which will decrease the incidence of severe, or drug-treated, hypoglycemia, the increasing pressure of cost-effectiveness across all markets, which will continue to pose a barrier to the reimbursement of novel glucagons.
What is the country-based hypoglycemia drug trends in the market?
Diagnosed incidence of hypoglycemia attributed to type 1 diabetes
In 2020, the UK had the highest diagnosed incidence with 29.65 cases per 100,000 population, while Spain had the lowest diagnosed incidence with 2.15 cases per 100,000 population. There were overall decreasing trends in the diagnosed incidence of hypoglycemia attributed to T1D in the US and Italy, and a less pronounced decrease in Japan. In the UK, there was a substantial overall increase in incidence across the forecast and these patterns were being driven by the corresponding trends in T1D incidence in each market.
Diagnosed incidence of hypoglycemia attributed to type 2 diabetes
In 2020, Germany had the highest diagnosed incidence while Japan had the lowest diagnosed incidence. In Germany and France, incidence trended downward during the first part of the forecast, before increasing again beginning in 2018 and 2022, respectively. Incidence decreased across the forecast in the US, from 244.32 cases per 100,000 population in 2010 to 161.42 cases per 100,000 population in 2030. In the UK, the incidence of hypoglycemia attributed to T2D increased across the forecast and these patterns are driven by the corresponding trends in T2D incidence in each market.
How many hospitalized severe incident cases of hypoglycemia are attributed to T1D?
Among severe cases of hypoglycemia attributed to T1D, there were 652 hospitalized incident cases of hypoglycemia. The US contributed the most of any market with 469 (71.93%) hospitalized cases, while Spain contributed the least with seven (1.07%) cases.
How has the global COVID-19 pandemic impacted the hypoglycemia drugs market?
People with T1D or T2D are more likely to become severely ill from COVID-19. Additionally, the COVID-19 pandemic has negatively impacted routine diabetes management and access to care. However, the extent of the COVID-19 pandemic’s impact on hypoglycemia is currently unknown.
What are the key players in the hypoglycemia drugs market?
Since the launch of glucagon therapies, Eli Lilly and Novo Nordisk have single-handedly dominated the glucagon market. Companies such as Eli Lilly, Novo Nordisk, Xeris Pharmaceuticals, Fresenius Kabi, Amphastar Pharmaceuticals, are found to be the major players for the Hypoglycemia drugs market. Furthermore, Eiger BioPharmaceuticals, Zeal & Pharma companies will be future players in the Hypoglycemia Drugs Market.
Hypoglycemia drug market, by key players
For more insights, download a free report sample
Market report scope
(Year – 2020)
|Growth rate||CAGR of >4% from 2021 to 2025|
|Base year for estimation||2020|
|Market segments by country||The US, France, Germany, Italy, Spain, the UK and Japan|
|Key players||Eli Lilly, Novo Nordisk, Xeris Pharmaceuticals, Fresenius Kabi, Amphastar Pharmaceuticals, Eiger BioPharmaceuticals and Zeal and Pharma|
This report provides a comprehensive analysis of the Hypoglycemia Drug market-
- Overview of hypoglycemia including epidemiology, disease etiology and management.
- Topline hypoglycemia drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global hypoglycemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global hypoglycemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hypoglycemia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global hypoglycemia therapeutics market from 2020-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
| List of Tables
| List of Figures
| About GlobalData
1 Hypoglycemia: Executive Summary
1.1 The Hypoglycemia Market Will Grow to
675.1M by 2030
1.2 New Hypoglycemia Players Are Focusing on Increasing Ease-of-Use and Integration with Technologies
1.3 There Are Few Unmet Needs for Hypoglycemia That Can Be Addressed Therapeutically
1.4 Pipeline Therapies and Device Integration Could Greatly Impact the Incidence of Severe Events
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.3.1 Diagnosed Incidence of Hypoglycemia Attributed to Type 1 Diabetes
4.3.2 Diagnosed Incidence of Hypoglycemia Attributed to Type 2 Diabetes
4.4 7MM Forecast Methodology
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.4.4 Diagnosed Incident Cases of Type 1 Diabetes
4.4.5 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes
4.4.6 Diagnosed Incident Cases of Type 2 Diabetes
4.4.7 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes
4.4.8 Diagnosed Incident Cases of Non-Diabetic Hypoglycemia
4.4.9 Diagnosed Incident Cases of Hypoglycemia in Bariatric Surgery Population
4.5 Epidemiological Forecast for Hypoglycemia (2020–2030)
4.5.1 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes
4.5.2 Age-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes
4.5.3 Sex-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes
4.5.4 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes by Severity
4.5.5 Hospitalized Severe Incident Cases of Hypoglycemia Attributed to Type 1 Diabetes
4.5.6 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes
4.5.7 Age-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes
4.5.8 Sex-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes
4.5.9 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes by Severity
4.5.10 Hospitalized Severe Incident Cases of Hypoglycemia Attributed to Type 2 Diabetes
4.5.11 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 and Type 2 Diabetes
4.5.12 Age-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 and Type 2 Diabetes
4.5.13 Sex-Specific Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 and Type 2 Diabetes
4.5.14 Diagnosed Incident Cases of Hypoglycemia Attributed to Type 1 and Type 2 Diabetes by Severity
4.5.15 Hospitalized Severe Incident Cases of Hypoglycemia Attributed to Type 1 and Type 2 Diabetes
4.5.16 Diagnosed Incident Cases of Non-Diabetic Hypoglycemia
4.5.17 Diagnosed Incident Cases of Hypoglycemia in the Bariatric Surgery Population
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Patient Hypoglycemia Self-Management Practices Across the 7MM
5.3 Severe Hypoglycemia Treatment Practices Across the 7MM
5.3.1 Hospitalization Across the 7MM Markets
5.4 Non-diabetic Hypoglycemia Management Across the 7MM
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.2 Treatments for Non-diabetic Hypoglycemia
7.3 Severe Hypoglycemia Prevention
7.4 Ease of Glucagon Administration
7.5 Glucagon Cost
7.6 Hypoglycemia Awareness
8 R&D Strategies
8.2 Clinical Trials Design
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Competitive Assessment
11 Current and Future Players
11.2 Eli Lilly
11.3 Novo Nordisk
11.4 Amphastar Pharmaceuticals
11.5 Zealand Pharma
11.6 Xeris Pharmaceuticals
11.7 Eiger Biopharmaceuticals
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers – Global Issues
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4.2 Key Events
12.4.3 Drivers and Barriers
13.3.1 Forecasting Methodology
13.4 Primary Research – KOLs Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.2 Therapy Area Director
13.6.4 Managing Epidemiologists
13.6.5 Global Director of Therapy Analysis and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
| Contact Us
Frequently asked questions
What is the value of the hypoglycemia drug market in 2020?
The hypoglycemia drug market was valued at $423.5 million in 2020.
What is the growth rate of the hypoglycemia drug market?
The hypoglycemia drug market is projected to grow at a CAGR of more than 4% during the period 2021-2025.
What are the key countries in the hypoglycemia drug market?
There are seven major pharmaceutical markets (7MM) covered in this report: the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan.
Who are the key market players in the hypoglycemia drug market?
Eli Lilly, Novo Nordisk, Xeris Pharmaceuticals, Fresenius Kabi, Amphastar Pharmaceuticals, Eiger BioPharmaceuticals and Zeal and Pharma are the key market players in the hypoglycemia drug market.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.